Measles virus as an oncolytic immunotherapy

• Verfasst von: Engeland, Christine Elisabeth [VerfasserIn]
• Verfasst von: Ungerechts, Guy [VerfasserIn]
• Titel: Measles virus as an oncolytic immunotherapy
• Verf.angabe: Christine E. Engeland and Guy Ungerechts
• E-Jahr: 2021
• Jahr: 1 February 2021
• Umfang: 18 S.
• Fussnoten: Gesehen am 01.12.2021
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2021
• Band/Heft Quelle: 13(2021), 3, Artikel-ID 544, Seite 1-18
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers13030544
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cancer immunotherapy
• Sach-SW: immune checkpoint blockade
• Sach-SW: measles virus
• Sach-SW: oncolytic virus
• Sach-SW: vaccination
• Sach-SW: vector engineering
• K10plus-PPN: 1750843471

Abstract

Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity. Live attenuated MeV vaccine strains are therefore under investigation as cancer therapeutics. The versatile MeV reverse genetics systems allows for engineering of advanced targeted, armed, and shielded oncolytic viral vectors. Therapeutic efficacy can further be enhanced by combination treatments. An emerging focus in this regard is combination immunotherapy, especially with immune checkpoint blockade. Despite challenges arising from antiviral immunity, availability of preclinical models, and GMP production, early clinical trials have demonstrated safety of oncolytic MeV and yielded promising efficacy data. Future clinical trials with engineered viruses, rational combination regimens, and comprehensive translational research programs will realize the potential of oncolytic immunotherapy.